Early data suggests AI-designed drug rentosertib could slow aging, NYT reports
coherence · x · 2026-09-07
The New York Times reports that Insilico Medicine says clinical trial data for rentosertib, its AI-generated drug candidate for chronic lung disease, hints at a second benefit: slowing aging.
- The drug's molecular structure was designed with generative AI; a prior trial showed it could help treat chronic lung disease
- New results published in Nature Biotechnology show the drug reduced biological markers of age as measured by six "aging clocks" — AI models that predict morbidity and mortality
- Reporter Cade Metz calls the trial a milestone in the broader effort to apply chatbot-era AI techniques to drug discovery; Insilico is one of many startups, tech giants, and academic labs in the space
More from Apps
- tldraw flash lets you create animations from scratch or remix ready-made templates — max__drake · 2026-09-08
- minoHealth's Moremi AI featured on CNN for breast cancer diagnosis — Ghost_Pilot_MD · 2026-09-08
- ChatGPT Sites lets you build and publish full websites by chatting, paid plans only — aitrendz_xyz · 2026-09-08
- Jimmy Koppel: which app conventions can AI overthrow? Let players filter for kind messages only — jimmykoppel · 2026-09-08
- Indie Dev Ships Qiaomu AI RSS: An Obsidian Plugin That Translates and Aggregates 46 AI Newsletters — vista8 · 2026-09-08
- AI filmmaking gains a pre-production layer: spatial planning before generation — HeyNayeem · 2026-09-08